Post-traumatic Stress Disorder Treatment Market, by Drug Class (Antidepressants, Anti-anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics or Second Generation Antipsychotics (SGOs), Beta-Blockers, and Others (Benzodiazepines and Others)),

Post-traumatic Stress Disorder Treatment Market, by Drug Class (Antidepressants, Anti-anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics or Second Generation Antipsychotics (SGOs), Beta-Blockers, and Others (Benzodiazepines and Others)), by Route of Administration (Oral, Parenteral, and Nasal), by Age Group (Pediatric, Adult, and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc. Symptoms of PTSD may generate after three months or even after a year. Most of the patients suffering from PTSD show symptoms like intrusive memories, avoidance, negative changes in thinking and changes in emotional and physical reactions. For instance, sudden death of a loved one may cause PTSD in some people. People with PTSD have heightened sense of danger. According to the U.S. National centre for PTSD, it is estimated that about 15% of the veterans of Vietnam War and 12% of gulf war veterans have PTSD. According to American Psychiatric Association, women are twice likely to get PTSD as compared to men. Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.

Market Dynamics

Increasing research and development activities by the key market players for the treatment of post-traumatic stress disorder is expected to boost the growth of the global post-traumatic stress disorder treatment market over the forecast period. For instance, in December 2021, Jazz Pharmaceuticals plc. a pharmaceutical company, announced that the company had enrolled its first patient in Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme Fatty Acid Amide Hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patient’s associated symptoms such as anxiety, insomnia, and nightmares.

Key features of the study:

• This report provides an in-depth analysis of the global post-traumatic stress disorder treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global post-traumatic stress disorder treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Jazz Pharmaceuticals plc., Madrigal Mental Care, Allergan PLC, Otsuka Pharmaceutical Co., Ltd., apex laboratories Pvt. Ltd., H. Lundbeck A/S (Lundbeck), Neurovation Labs, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc., Aurobindo Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceuticals Industries Ltd., and Mylan Pharmaceuticals (Viatris Inc.)
• Insights from this report would allow marketers and management authorities of companies to make an informed decision for their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global post-traumatic stress disorder treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global post-traumatic stress disorder treatment market

Detailed Segmentation:

• Global Post-traumatic Stress Disorder Treatment Market, By Drug Class
• Antidepressants
• Anti-anxiety
• Antihypertensive
• Monoamine Oxidase (MAOs)
• Antipsychotics or Second Generation Antipsychotics (SGOs)
• Beta-Blockers
• Others (Benzodiazepines and Others)
• Global Post-traumatic Stress Disorder Treatment Market, By Route of Administration:
• Oral
• Parenteral
• Nasal
• Global Post-traumatic Stress Disorder Treatment Market, By Age Group:
• Pediatric
• Adult
• Geriatric
• Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Post-traumatic Stress Disorder Treatment Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Jazz Pharmaceuticals plc.*
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Madrigal Mental Care
• Allergan PLC
• Otsuka Pharmaceutical Co., Ltd.
• apex laboratories Pvt. Ltd.
• Lundbeck A/S (Lundbeck)
• Neurovation Labs, Inc.
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Sun Pharmaceuticals Pvt Ltd
• Bristol-Myers Squibb
• Johnson and Johnson
• Pfizer Inc.
• Aurobindo Inc.
• Amneal Pharmaceuticals LLC
• Teva Pharmaceuticals Industries Ltd.
• Mylan Pharmaceuticals (Viatris Inc.)

“*” marked represents similar segmentation in other categories in the respective section.